Literature DB >> 3411161

Combined treatment of colon adenocarcinoma in rats with tumor necrosis factor and the interferon inducer ABPP.

R L Marquet1, A M Eggermont, R W de Bruin, W Fiers, J Jeekel.   

Abstract

It is well documented that the antitumor capacity of tumor necrosis factor (TNF) can be enhanced by interferons (IFNs), notably IFN-gamma. The aim of this study was to investigate the efficacy of a combined treatment with TNF and the IFN-inducer 2-amino-5-bromo-6-phenyl-4-pyrimidinone (ABPP) on a transplantable colon carcinoma (CC531) in rats. The tumor was implanted under the kidney capsule of syngeneic rats; the tumors were removed a week after implantation and growth was assessed by weighing. The animals were treated with 1 microgram of TNF, given i.v. on days 0, 2, and 4; and with 250 mg/kg of ABPP, administered i.p. on days 0 and 1. The results of two separate experiments indicated that both TNF and ABPP had a significant inhibitory effect on tumor growth. Combined, the two agents were found to act additively. In the dosage used, TNF toxicity was mild, transient, and not influenced by ABPP.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3411161     DOI: 10.1089/jir.1988.8.319

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  3 in total

1.  The antitumour activity of the interferon inducer bropirimine is partially mediated by endogenous tumour necrosis factor alpha.

Authors:  M Scheringa; J N IJzermans; J Jeekel; R L Marquet
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

2.  Comparative computational studies of 3,4-dihydro-2,6-diaryl-4-oxo-pyrimidine-5-carbonitrile derivatives as potential antinociceptive agents.

Authors:  Janaína V dos Anjos; Rajendra M Srivastava; João H Costa-Silva; Luciana Scotti; Marcus T Scotti; Almir G Wanderley; Elisa Soares Leite; Sebastião J de Melo; Francisco J B Mendonça Junior
Journal:  Molecules       Date:  2012-01-16       Impact factor: 4.411

3.  Multidrug resistance in rat colon carcinoma cell lines CC531, CC531mdr+ and CC531rev.

Authors:  E Gheuens; S van der Heyden; H Elst; A Eggermont; A Van Oosterom; E De Bruijn
Journal:  Jpn J Cancer Res       Date:  1993-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.